Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2021 23:58 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 03, 2021 23:35 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 03, 2021 17:51 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
February 01, 2021 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch

DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
January 25, 2021 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 -- DUBLIN, Ireland and CHICAGO, Jan. 25, 2021 ...
January 06, 2021 17:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference

DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
December 23, 2020 07:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities-- DUBLIN, Ireland and...
December 21, 2020 17:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

DUBLIN, Ireland and CHICAGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
December 07, 2020 08:00 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority

DUBLIN, Ireland and CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
November 30, 2020 09:15 ET | Source: Iterum Therapeutics plc

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

--First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved-- --Potential Approval Q3 2021 with Priority Review-- DUBLIN, Ireland and CHICAGO, Nov. 30,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right